Japanese researchers said Friday that they transplanted so-called "iPS" stem cells in the brain of a patient with Parkinson's disease, the first attempt in the world.
The Kyoto University team injected 2.4 million of these pluripotent cells, can provide some type of cell, in the left part of brain, during a three-hour operation last month.
The man, in his fifties, was well tolerated and will now be supervised for two years, said the Kyotuniversity in a statement.
If no problems occur in the next six months, researchers will implant 2.4 million more cells, this time in the right-hand part of the patient's brain.
These iPS cells from healthy donors are believed to develop into neurons that produce dopamine, a neurotransmitter involved in engine control.
Kyoto University announced its holding of this in July clinical trial with seven participants aged 50 to 69 years.
"I greet the patients for their courageous and determined participation"commented Professor Jun Takahashi, quoted Friday by NHK's public television channel.
the Parkinson's disease is marked by degeneration of these neurons resulting in progressively impaired symptoms such as tremor, stiff stiffness and decreased body movement.
It affects more than 10 million people worldwide, according to the US Parkinson Foundation. The current available therapies "improve the symptoms without slowing down progression of the disease"says this reason.
This new research aims at reducing evil.
This test follows an experiment performed monkeys with stem cells of human origin that have made it possible to improve the ability of primates suffering from Parkinson's disease to make movements, according to a study published in late August 2017 in the scientific journal Nature. Survival of grafted cells, by injection into the primates, was observed for two years without any tumor appearance.
the induced pluripotent stem cells (iPS for induced pluripotent stem cells), adult cells are returned to the nearest embryonic state by again expressing four genes (usually inactive in adult cells). this genetic manipulation gives them back the possibility of producing some form of cells (pluripotency), depending on where in the body they are transplanted.
The use of iPS cells does not constitute basic ethical problems, as opposed to stem cells taken from human embryos.